HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Tirzepatide cut diabetes risk over 90% in obesity and prediabetes over three years

Gokhan Can · Nov 26, 2024 · ♥ 3 reactions · 1 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Insulin resistance & diabetes
AI summary & key facts

Gokhan links a News-Medical report that tirzepatide (Zepbound) reduced the risk of developing diabetes by more than 90% over three years compared with placebo in patients with obesity and prediabetes. No further commentary is added.

News-MedicalTirzepatide cuts diabetes risk by 90% in obese patients, study showsTirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other…news-medical.net

Research cited

#diabetes#obesity#prediabetes
← newer: Review: moderate coffee intake linked to lower mortality andolder: Dr Gil Carvalho: evidence contradicts RFK Jr's claims that s →